Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Payables (2016 - 2025)

Historic Payables for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $5.2 million.

  • Harvard Bioscience's Payables fell 202.54% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 202.54%. This contributed to the annual value of $4.8 million for FY2024, which is 1380.99% down from last year.
  • Latest data reveals that Harvard Bioscience reported Payables of $5.2 million as of Q3 2025, which was down 202.54% from $4.7 million recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Payables registered a high of $7.5 million during Q2 2021, and its lowest value of $4.7 million during Q2 2023.
  • For the 5-year period, Harvard Bioscience's Payables averaged around $5.7 million, with its median value being $5.7 million (2024).
  • Its Payables has fluctuated over the past 5 years, first skyrocketed by 3127.67% in 2022, then tumbled by 3074.89% in 2023.
  • Over the past 5 years, Harvard Bioscience's Payables (Quarter) stood at $4.9 million in 2021, then surged by 31.28% to $6.4 million in 2022, then dropped by 13.85% to $5.6 million in 2023, then dropped by 13.81% to $4.8 million in 2024, then rose by 8.13% to $5.2 million in 2025.
  • Its Payables was $5.2 million in Q3 2025, compared to $4.7 million in Q2 2025 and $4.8 million in Q1 2025.